

**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES  
February 11, 2014**

The meeting was called to order at approximately 1:52 p.m. on Tuesday, February 11, 2014.

Committee members present: Melissa Bowlby, PA-C; James Zedaker, PA-C; Margaret Huwer, Pharm.D.; Anita Steinbergh, D.O.; James Fry, PA-C; and Teresa Ash, Pharm.D.

Staff members present: Sallie Debolt, and Cathy Hacker

Guests: Beth Adamson, Executive Director, OAPA

**I. Review of the October 8, 2013 and the December 10, 2013 minutes.**

Mr. Zedaker moved to approve the minutes from the October 8, 2013 minutes. Dr. Steinbergh seconded the motion. All members voted aye. The motion carried.

Dr. Steinbergh moved to approve the December 10, 2013 minutes. Mr. Fry seconded. All members voted aye. The motion carried.

**II. Formulary Review**

The committee considered the following medications and made these changes to the formulary:

**Rayos: already in the CTP may prescribe category no change**

**Fycompa: already in the physician initiated (PI) category no change**

**Fulyzaq: added to the formulary as PI category as this is a medication used for diarrhea associates with antiretroviral therapy. (Mr. Fry opposed this change as he felt it should be CTP may prescribe category).**

**Nesina: already in the CTP may prescribe category no change**

**Kynamro: was placed in the PI category as this is a new class of medications used by Lipidologists and should not be used by primary care offices.**

**Suclear: already in the CTP may prescribe category no change**

**Ravicti: already in the CTP may not prescribe category no change**

**Osphena: already in the CTP may prescribe category no change**

**Pomalyst: already in the CTP may not prescribe category no change**

**Lymphoseek Kit: this was added to the PI category due to the specific use for melanoma or breast cancer**

**Tecfidera: already in the CTP may not prescribe category no change**

**Dotarem: was added to the PI category due to the black box warnings**

**Tafinlar: already in the CTP may not prescribe category no change**

**Xofigo: already in the CTP may not prescribe category no change**

**Mekinist: already in the CTP may not prescribe category no change**

**Breo Ellipta: already in the CTP may prescribe category no change**

**Vibativ: already in the CTP may not prescribe category no change**

Dr. Steinbergh moved to approve the formulary as amended. Mr. Zedaker seconded the motion. Mr. Fry voted opposed the category that Fulyzaq was placed in. All members voted aye. The motion carried.

The committee then moved the discussion to the request from Merck & Co that is requesting that Nuvaring be added to the formulary as CTP may prescribe instead of the PI category that they are currently in.

Mrs. Ash stated that she had reviewed the non-oral contraceptives in the PI category and feels that Nuvaring is safe for PA's to prescribe. Mr. Fry and Dr. Steinbergh both questioned why Depoprovera and other non-oral contraceptives are in the PI category.

Dr. Steinbergh move to approve moving contraceptives to the CTP may prescribe category. Mr. Fry seconded the motion. All members voted aye. The motion carried.

The committee reviewed the request from Amanda Rahn, PA-C that is requesting clarification of Naltrexone versus Naloxone as it is presented in the formulary.

Ms. Rahn states that the only place in the formulary that naltrexone is listed is under antidotes where it says that CTP holder may prescribe it for the resuscitation of narcotic overdose, however she believes that this is an error because naltrexone is not FDA approved for this indications. She states that naloxone is the antidote for narcotic overdose. Mrs. Ash states that Naltrexone is in the wrong place as it is used to treat for drug and alcohol dependence. The law says PA's cannot treat opioid dependence with a scheduled medication however naltrexone is not a scheduled medication. PA' s that are prescribing these medication should be working with an addiction specialist. Dr. Steinbergh indication that these medications can be abused however felt that if a patient presented to the ER who has an established prescriptions with his/her physician and missed an appointment the patient should be able to get a refill to hold them until they can get back to their treating physician. Mr. Fry stated that this is not a highly abused medication. Mrs. Ash and Dr. Steinbergh both had concerns regarding patients not keeping appointments with their treating physician. Ms. Bowlby suggested that the committee put these medications into the PI category and see if the need to change them to CTP may prescribe arises. Dr. Steinbergh indicated that PA's should not be subjected to these situations all the time and the PI category is a safe place to start.

Dr. Steinbergh moved to place Naloxone and Naltrexone into the PI category of the PA formulary. Mr. Fry seconded the motion. All members voted aye. The motion carried.

### ***III. Review Special Services applications***

The committee discussed the application from Orthopaedic Institute of Ohio that is requesting approval of: subacromial bursa injections.

The committee noted that this application met the supervision and education requirements that have been previously approved for these injections.

Mr. Fry moved to approve this application as written. Mr. Zedaker seconded the motion all members voted aye. The motion carried.

The committee discussed the application from Orthopaedic Institute of Ohio that is requesting approval of: Greater Trochanter Bursa injections.

The committee noted that this application meets the training, supervision and education requirements that have been previously approved for these injections.

Mr. Fry moved to approve this application as written. Mr. Zedaker seconded the motion all members voted aye. The motion carried.

**IV. New Business matters**

Ms. Bowlby indicated that she had received an email from a colleague who was concerned that the statement on the Board's website regarding PA's working in an urgent care or retail clinic setting was a new policy. They had questions as to why this statement was not reviewed with the PAPC prior to being placed on the Board's website. Ms. Debolt stated that it was based on concerns that there are PA's practicing who do not know who their supervisors are and supervising physicians of PA's that are unaware of the PA's whereabouts. Dr. Steinbergh stated that the Physician Assistant Committee of the Board has been dealing with this issue for months. Physicians are coming to the Committee asking for PA's to work alone and did not understand their supervisory duties as supervising physicians. This paper represents a clarification of the statutes and the supervision physicians responsibilities for physicians utilizing physician assistant's in these settings. This guidance statement came about as a result of a clarification letter that was sent to an urgent care physician. The Board is trying to clarify that it is not acceptable for PA's to engage in independent practice in these types of settings. It is necessary to have enough physicians to cover these facilities while the PA's are working.

Mr. Fry stated that this should have come to the PAPC before it was set as a policy statement. Dr. Steinbergh stated that Ms. Debolt would put a clarification statement on the website as to the intent of this paper. Ms. Debolt stated that this is just reiterating the law. Ms. Bowlby and Mr. Fry both stated that the PAPC should have known it was coming. Ms. Debolt said this was an attempt to help the staff and urgent care physicians understand the laws and rules.

Ms. Bowlby stated it would have been nice if it had been shared with her as the Chair of the committee so that she would not have been blindsided with phone calls and emails. Ms. Debolt apologized for the oversight.

Ms. Debolt informed the committee that the model orthopaedic plan should be on the next committee's agenda along with some revisions to the rules to make some minor changes to reflect the current statutes.

The Physician Assistant Policy Committee meeting was adjourned by Ms. Bowlby at approximately 2:48 p.m. on Tuesday, February 11, 2014.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on February 11, 2014.

---

Melissa Bowlby, PA-C  
Chair, PAPC

Copies of documents and/or materials referenced in the minutes of the Physician Assistant Policy Committee meeting are available at the Board offices.